Senti Biosciences is trading 6.55% down at $0.31 during open trading on September 8, 2026; the immediate catalyst remains unclear.
- Recent disclosures detailed a $2.0 million senior secured convertible-note issuance.
- The filings also described a conditional $2.5 million Celadon-affiliate equity commitment tied to a potential merger.
- No September 8 update or explicit link to the stock decline was provided.